Japanese firms Dainippon Sumitomo Pharma (DSP) and Takeda Pharmaceutical (Takeda) have received positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the use of lurasidone in the treatment of adults with schizophrenia.
CLICK ON TITLE BELOW
EMA panel issues positive opinion for DSP and Takeda's schizophrenia drug lurasidone
WPGPRWNB2ZDF
No comments:
Post a Comment